Clinical, Cognitive and Neural Effects of Potentiation of ECT by rTMS in Treatment-Resistant Depression

Study acronym: STIMAGNECT2
StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated April 30, 2024 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Electroconvulsive therapy (ECT) is one of the most effective treatments for treatment-resistant depression (TRD). However, due to response delay and cognitive impairment, ECT remains an imperfect treatment. In this multicenter, randomized, double-blind, sham-controlled study, our objective is to assess the priming effect of rTMS sessions before ECT on clinical, cognitive and neural response in patients with TRD.
Trial Details
NCT Number NCT06391723
Lead Sponsor Centre Hospitalier du Rouvray
Collaborators: University Hospital, Rouen, Centre Hospitalier Sainte Anne, Paris
Conditions
(from sponsor)		 Major Depressive Disorder
Related terms Depressive Disorder, Treatment-Resistant, Major Depressive Disorder
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov